Canada Markets open in 2 hrs 4 mins
  • S&P/TSX

    20,621.39
    -436.81 (-2.07%)
     
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • DOW

    34,265.37
    -450.03 (-1.30%)
     
  • CAD/USD

    0.7947
    -0.0052 (-0.6517%)
     
  • CRUDE OIL

    0 (0)
     
  • BTC-CAD

    42,336.23
    -2,864.79 (-6.34%)
     
  • CMC Crypto 200

    763.77
    +521.09 (+214.72%)
     
  • GOLD FUTURES

    1,836.10
    -6.50 (-0.35%)
     
  • RUSSELL 2000

    1,987.92
    -36.12 (-1.78%)
     
  • 10-Yr Bond

    1.7470
    0.0000 (0.00%)
     
  • NASDAQ futures

    14,411.00
    -430.00 (-2.90%)
     
  • VOLATILITY

    28.85
    +3.26 (+12.74%)
     
  • FTSE

    7,494.13
    -90.88 (-1.20%)
     
  • NIKKEI 225

    27,522.26
    -250.64 (-0.90%)
     
  • CAD/EUR

    0.7001
    -0.0066 (-0.93%)
     

Mexico approves emergency use of Lilly's COVID-19 treatment

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • LLY

MEXICO CITY, Dec 1 (Reuters) - Mexico's health regulator Cofepris said on Wednesday it had approved U.S. pharmaceutical firm Eli Lilly and Co's antibody treatment against COVID-19 for emergency use with infected patients at risk from comorbidities.

Cofepris said in a statement it had granted the emergency use of Lilly's injectable combination of bamlanivimab and etesevimab to treat mild to moderate cases of coronavirus in people above the age of 12 who weigh at least 40 kilograms.

The U.S. Food and Drug Administration had previously approved emergency use of the combination.

Cofepris noted that the Lily antibody treatment does not replace licensed COVID-19 vaccines. (Reporting by Raul Cortes Editing by Chizu Nomiyama)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting